Executive Leadership

EDE's Executive Leadership Team is the company's senior leadership and decision-making management body. It brings together our top leaders to focus on major financial, strategic and operational decisions for the company.

To maximize new opportunities in biomedical research, and bring more innovative medicines to more patients more quickly, EDE has created a Scientific Product Portfolio Management Board focused on product development decisions. Two distinct R&D groups have been established as well. The Pharmaceutical Therapeutics Research & Development Group focuses on the development of small molecules and related modalities; and The Biological Therapeutics Research & Development Group focuses on large-molecule research.

EDE has also developed an enhanced innovative virtual drug development network (VDD-EIN) structure which provides flexibility and effectiveness in decision making and product development.  The VDD-EIN enables us to rapidly capitalize on opportunities to advance our business, increase support for successful development of new medicines, forge partnerships with key customers, timely enter into co-promotion and licensing agreements, invest in new technologies to add value to our core product offerings,  and leverage services from outside the company.
 
EDE has four majors business units: Rare and neglected diseases, Oncology, CNS and pediatrics. The businesses are provided with the resources to pursue attractive growth opportunities and to deliver benefits to all who rely on us around the world.

BOARD OF DIRECTORS

MANAGEMENT TEAM

Renay A. Ebelle, PhD, MBA

President & Chief Executive Officer

Jacqueline Philips, MD, MBA

Vice-President Clinical Affairs

Christiano Butler

Head of Operations